UK ABHI 2019: Correct Diagnosis Must Be Followed By Appropriate Therapy
Executive Summary
The current hiatus in the Brexit debate has left room for other themes of clinical and commercial importance to the UK medtech industry to rise back to the surface of the national debate. The potential value of the Long Term Plan and innovation adoption and spread, among others, will share top billing at the ABHI’s 2019 UK Market Conference, in mid-June.
You may also be interested in...
Well-Intentioned, But Can The Improved AAC Work For UK Medtechs?
The newly enhanced Accelerated Access Collaborative (AAC) promises a more concerted effort to ensure health-care innovations reach end users. On paper, it looks good, but the medtech industry in the UK has seen several worthy efforts along similar lines ultimately amount to little. Health Enterprise East’s Dr. Anne Blackwood is reserving judgment.
UK Medtech Market Access: More About Mindset Than The Money
The journey from medtech concept to implementation is long and slow, and new ideas often don’t make it all the way to manufacturing and approval. But when they do, what is needed is a system that guarantees adoption and usage of those proven, innovative solutions that clear the many hurdles en route to clinical practice.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.